Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Katja Weisel
Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
To the Editor, Targeting B-cell maturation antigen (BCMA) has transformed the relapsed/refractory multiple myeloma (RRMM) landscape with unprecedented overall survival (OS) outcomes versus standard-of-care triplet regimens. Belantamab mafodotin, an anti-BCMA antibody-drug conjugate, has a multimodal mechanism of action involving minimal immunosuppression and no evidence of induction of T-cell exhaustion [1, 2].
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma
|
Abstract In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Here, we report an updated subgroup analysis by frailty status.
By Thierry Facon, Gordon Cook, Saad Usmani, Cyrille Hulin, Shaji Kumar Verified, Cyrille Touzeau, Nizar Bahlis, Supratik Basu, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty Verified, Christopher P. Venner, Katja Weisel, Noopur Raje, Salomon Manier, Mai T. Ngo, Kasey Bolyard, Fredrik Borgsten, Robin Carson, Sonja Zweegman, Marjohn Armoon
|
Nature
Verified
A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma
Dear Editor, G-protein–coupled receptor family C group 5 member D (GPRC5D) is a leading immunotherapy target in multiple myeloma (MM), with diverse GPRC5D-targeting agents—including T-cell engagers (TCE), antibody–drug conjugates, and chimeric antigen receptor (CAR) T cells—being evaluated clinically for relapsed/refractory MM.
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
|
Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report results on long-term OS and subsequent antimyeloma therapies from the MAIA final analysis. A protocol amendment (July 20, 2021) led to a long-term extension of MAIA, during which patients were followed for OS.
By Thierry Facon, Shaji Kumar Verified, Robert Orlowski, Nizar Bahlis, Philippe Moreau, Hartmut Goldschmidt, Supratik Basu, Cyrille Hulin, Sonja Zweegman, Katja Weisel, Aurore Perrot, Caroline Jacquet, Noopur Raje, Salomon Manier, Ajai Chari, Markus Hansson, Mohamad Mohty Verified, Michel Delforge, Torben Plesner, Gordon Cook, Xavier Leleu, Hang Quach, Christopher P. Venner, Mourad Tiab, Margaret Macro, Laurent Frenzel, George Wang, Huiling Pei, Robin Carson, Fredrik Borgsten, Saad Usmani, Kasey Bolyard
|
Nature
Verified
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial
|
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04471-x, published online 25 June 2026.
By Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Roland Fenk, Katja Weisel, Lilli Podola, Uta Bertsch, Alexander Brobeil, Julia Mersi, Stefanie Huhn, Ryan Arlinghaus, Michael Hundemer, Stephan Bohl, Elias K. Mai, Natalie Schub, Johannes M. Waldschmidt, Florian Bassermann, Carsten Müller-Tidow, Christoph J. Heuck, Caline Sakabedoyan, Josephine Khan, Elena Ershova, Bas D. Koster, Monika Engelhardt, Mathias Hänel, Hans Salwender, Raphael Teipel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche
|
Nature
Verified
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial
|
Abstract Advancements in frontline therapies have substantially improved outcomes in newly diagnosed multiple myeloma (NDMM); however, many patients will not achieve deep responses and will relapse. Teclistamab, a BCMA×CD3 bispecific antibody, in combination with daratumumab, has demonstrated strong efficacy in relapsed/refractory multiple myeloma versus standard of care as early as first relapse.
By Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Roland Fenk, Katja Weisel, Uta Bertsch, Alexander Brobeil, Stefanie Huhn, Michael Hundemer, Stephan Bohl, Elias K. Mai, Natalie Schub, Johannes M. Waldschmidt, Florian Bassermann, Carsten Müller-Tidow, Christoph J. Heuck, Elena Ershova, Bas D. Koster, Monika Engelhardt, Mathias Hänel, Hans Salwender, Raphael Teipel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche, Lilli Podola, Julia Mersi, Ryan Arlinghaus, Caline Sakabedoyan, Josephine Khan
|
Nature
Verified
Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma
Abstract Use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy to treat relapsed/refractory multiple myeloma is increasing. Studies suggest that effective bridging therapy (BT) prior to anti-BCMA CAR-T therapy can enhance efficacy and safety outcomes.
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial
|
Abstract Induction and consolidation with a quadruplet therapy of a CD38-targeting monoclonal antibody, a proteasome inhibitor, an immunomodulatory drug and dexamethasone are a standard-of-care treatment in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM) with the optimal drugs to be used still under debate.
By Francesca Gay, Meletios A. Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol, Eirini Katodritou, Paula Otero, Roman Hajek, Elisabetta Antonioli, Mark van Duin, Mattia D’Agostino, Joaquín Martínez-López, Elena Zamagni, Niels W. C. J. van de Donk, Katja Weisel, Jakub Radocha, Angelo Belotti, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl, Wilfried Roeloffzen, Elena M. van Leeuwen-Segarceanu
|
Nature
Verified
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
|
Abstract LINKER-MM1 (NCT03761108) is a Phase 1/2 study of linvoseltamab, a human BCMA×CD3 bispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed (TCE) with ≥3 prior lines of therapy (3L+), or triple-class refractory (TCR).
By Shaji Kumar Verified, Katja Weisel, Paul Spin, Nicolle A. Bonar, Muhaimen Siddiqui, Mostafa Shokoohi, Di Wang, Kevin Hou, Michael West, Christian Hampp, Jeannette Green, James Harnett, Olivier Humblet, Alexander Breskin, Wenzhen Ge, Jessica J. Jalbert, Rachel Sobel, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Sundar Jagannath
|
Nature
Verified
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
|
Abstract LINKER-MM1 (NCT03761108) is a Phase 1/2 study of linvoseltamab, a human BCMA×CD3 bispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed (TCE) with ≥ 3 prior lines of therapy (3L+), or triple-class refractory (TCR).
By Shaji Kumar Verified, Sundar Jagannath, Katja Weisel, Laura Rosiñol, Xavier Leleu, Meletios-Athanasios Dimopoulos, Efstathios Kastritis, David Siegel, Jorge Monge, Juan Du, Pedro Asensi Cantó, Jae Lee, Maria-Victoria Mateos, Borja Puertas, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Nicolle A. Bonar, Paul Spin, Mostafa Shokoohi, Di Wang, Kevin Hou, Michael West, Christian Hampp, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel Sobel, Jessica J. Jalbert, Karen Rodriguez Lorenc, Qiufei Ma, Brian Durie, Javier de la Rubia, Muhaimen Siddiqui, Jeannette Green, Glenn S. Kroog
|
Nature
Verified
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes - Leukemia
Abstract In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years).
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development - Blood Cancer Journal
Abstract Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who have received at least 4 prior lines of therapy, based on response rates observed in DREAMM-1/DREAMM-2.
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study - Leukemia
Abstract In the MAIA study (median follow-up, 56.2 months), daratumumab plus lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival (PFS) and overall survival versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM).
High5 Oncology TV: ASH 2024
Newly Diagnosed Multiple Myeloma The holy grail of MRD-negativity Reducing waste in Myeloma Belantamab mafodotin in 1st line of transplant-ineligible patients Maintenance to end all maintenance Great new developments in first-line therapy! Newly Diagnosed Multiple Myeloma multilanguage Belantamab Mafodotin in der Erstbehandlung der nicht transplantierten Patienten Tolle neue Entwicklungen in der Erstlinientherapie! Relapsed Refractory Multiple Myeloma A new trispecific to beat them all?
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis) | Leukemia
Abstract Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1–35.0). Patients (N = 248) had received median 4 prior LOT (range, 2–13) at enrollment.
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm - Blood Cancer Journal
Abstract Measurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is increasingly challenging to use OS as the primary endpoint if timely approval of novel agents is to be ensured to enable maximum benefit for patients.
CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study | Leukemia
To the editor: In the battle against multiple myeloma (MM), T cell strategies have emerged as crucial, exploiting their natural tumor-cell targeting ability to enhance patient outcomes. Recent studies underscore the dual roles of T cells in MM: while specific T cells can effectively target and destroy MM cells, regulatory T cells may block this response, highlighting the complexity of the immune environment in MM [1, 2].
Prognostic importance of splicing-triggered aberrations of protein complex interfaces in cancer
Abstract Aberrant alternative splicing (AS) is a prominent hallmark of cancer. AS can perturb protein-protein interactions (PPIs) by adding or removing interface regions of protein complexes encoded by individual exons. Identifying prognostic exon-exon interactions (EEIs) from PPI interfaces can help discover AS-affected cancer-driving PPIs that can serve as potential drug targets.
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
INTRODUCTION Despite significant advances with current novel therapies such as second- and third-generation proteasome inhibitors (PIs), immunomodulatory drugs, and monoclonal antibodies (mAbs), most patients with multiple myeloma (MM) ultimately develop disease resistance and subsequently experience relapse.1 Patients who receive multiple regimens of combination therapy are especially likely to develop drug resistance, with triple-class or penta-refractory disease remaining an urgent unmet...
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Research ExplorerPublicationsBelantamab mafodotin: an important treatment option for vuln... Bibliographical data
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients | Leukemia
Abstract Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005–2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both.
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma - Blood Cancer Journal
Abstract Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseline (480 patients) and at the pre-defined, consecutive time points after induction (444 patients), prior to maintenance (305 patients) and after one year of maintenance (227 patients).
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Abstract Despite advances in the treatment of multiple myeloma, it remains an incurable disease, with relapses and resistances frequently observed. Recently, immunotherapies, in particular, monoclonal antibodies, have become important treatment options in anticancer therapies. Elotuzumab is a humanized monoclonal antibody to signaling lymphocytic activation molecule F7, which is highly expressed on myeloma cells and, to a lower extent, on selected leukocyte subsets such as natural killer cells.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial | Journal of Clinical Oncology
Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor1-4 and immunomodulatory5-7 mechanism of action, demonstrating greater cytotoxicity toward multiple myeloma (MM) cells ex vivo compared with analogs of other CD38 antibodies.8 Daratumumab induces higher levels of complement-dependent cytotoxicity, similar levels of antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis, and, in the presence of Fc receptor crosslinking,...
Updates on Isatuximab in Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
INTRODUCTION In the past decade, therapies that are more effective and less toxic have transformed the treatment landscape for patients with MM.
Overview of Biochemical vs Clinical Relapse in Myeloma
Nina Shah, MD: This is a very common situation. People are on lenalidomide maintenance, and when they’re on lenalidomide maintenance, we’re watching them very closely. It’s not like they just go off into the yonder. We have to check their laboratory test results, sometimes monthly, because of the CBC [complete blood count], so we often detect biochemical relapse or progression either way. Katja, how do you think biochemical vs clinical relapse is defined?
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
ORIGINAL ARTICLE Paul G. Richardson, Corresponding Author paul_richardson@dfci.harvard.edu Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Correspondence Paul G.
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
Abstract To understand the profile of best responders (complete response or better [≥CR]) to carfilzomib, we described the characteristics, progression-free survival (PFS), overall survival (OS) data, and the safety of patients who achieved ≥CR to carfilzomib-based treatment in ASPIRE and ENDEAVOR. In post hoc analyses from ASPIRE and ENDEAVOR, median PFS and OS were longer for ≥CR patients versus those who achieved a very good partial response or partial response (VGPR/PR).
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Abstract In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT).
Rebooting the Myeloma Treatment Programme
Steady Stream and Changing Seas in Myeloma Professor Jesús San Miguel Treatment of MM requires a multifaceted approach using a combination of therapies targeting the several pathophysiological pathways involved in the disease.
The case for longer treatment in MM: Part 1
Katja Weisel, MD In Part 1 of this editorial, Katja Weisel, MD, of University Hospital Tubingen in Germany, describes the benefits of longer treatment in multiple myeloma. Despite recent progress in advancing the care of patients with multiple myeloma (MM), this cancer remains incurable.
The case for longer treatment in MM: Part 2
Micrograph showing MM In Part 2 of this editorial, Katja Weisel, MD, of University Hospital Tubingen in Germany, addresses the barriers to longer treatment in multiple myeloma. Attitudes regarding longer treatment can present barriers to widespread adoption of this approach in multiple myeloma (MM).
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
MM-013, a noncomparative, European phase II trial, enrolled three patient cohorts: moderate RI (cohort A; estimated glomerular filtration rate, 30 to < 45 mL/min/1.73 m 2 ); severe RI (cohort B; estimated glomerular filtration rate, < 30 mL/min/1.73 m 2 ); and severe RI that requires hemodialysis (cohort C). Patients received pomalidomide 4 mg/d on days 1 to 21 and LoDEX 20 or 40 mg once per week in 28-day cycles. The primary end point was overall response rate.
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis
Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs is important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management. This analysis included 1088 patients who received ?
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Katja
Contact Katja, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack